ADHDNCT05635318
Quantitative EEG Neurofeedback as an Add-on Therapy For Attention-deficit Hyperactivity Disorder (ADHD)
A study testing FDA approved medications for ADHD plus Quantitative EEG Neurofeedback and FDA approved medications for ADHD in people with ADHD, run by Assiut University.
Trial summary
Attention deficit/hyperactivity disorder (ADHD) is a common neurological disorder in children, mainly manifesting as attention deficit, excessive hyperactivity, and impulsivity. It is a chronic condition that affects millions of children and often continues into adulthood. Read more about this study
- Who is it for?
- Ages 4 to 16 years
- Conditions the study is for
- ADHD
- What is being tested?
- FDA approved medications for ADHD plus Quantitative EEG Neurofeedback and FDA approved medications for ADHD
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 102 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2023to 1 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Patients diagnosed with ADHD according to DSM-5 Criteria for ADHD Age group: 4 years up to less than 16 years
Who cannot join
- *Any patient with other neurological or psychological diseases e.g. Epilepsy, Autism, Cerebral palsy
- Any patient in a different age group
Trial locations and contacts
No sites are listed yet.
About this study
Attention deficit/hyperactivity disorder (ADHD) is a common neurological disorder in children, mainly manifesting as attention deficit, excessive hyperactivity, and impulsivity. It is a chronic condition that affects millions of children and often continues into adulthood.
The prevalence of ADHD in the worldwide is approximately 5%, predominantly occurring in boys, and more than half of patients continue to experience symptoms into adulthood. Children with ADHD have moral disorders and learning difficulties, and these factors will seriously affect their academic achievements and familial and social relationships; thus, treatment is necessary.
Read more
Currently, the treatment for ADHD is usually pharmacological intervention, such as methylphenidate, Atomoxetine…. etc. However, research has suggested that pharmacological intervention has side effects on nervous system development in children, and the long-term efficacy is uncertain. In recent years, the efficacy of neurofeedback (NF) therapy, as a type of biofeedback method, has been proven in many diseases, such as mild cognitive impairment, epilepsy, and autism, depression, and anxiety.
NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training. This study adopts the theta/beta NF protocol. As a promising nonpharmacological alternative treatment for ADHD, the efficacy of NF has been proven in many studies.
The use of quantitative EEG neurofeedback as an add-on therapy can be markedly beneficial to shorten the period of pharmacological treatment and with minimal side effects.
Read the detailed description
Attention deficit/hyperactivity disorder (ADHD) is a common neurological disorder in children, mainly manifesting as attention deficit, excessive hyperactivity, and impulsivity. It is a chronic condition that affects millions of children and often continues into adulthood. ADHD includes a combination of persistent problems, such as difficulty sustaining attention, hyperactivity, and impulsive behavior. Based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), the American Psychiatric Association has divided ADHD into three subtypes: predominantly inattention (ADHD-I), predominantly hyperactive-impulsive (ADHD-HI) and a combination of both (ADHD-C) (1) The prevalence rate of ADHD in the worldwide is approximately 5%, predominantly occurring in boys, and more than half of patients continue to experience symptoms into adulthood (2). Most children with ADHD have moral disorders and learning difficulties, and these factors will seriously affect their academic achievements and familial and social relationships; thus, prompt treatment is necessary. (3) Historically, conventional EEG has added little to the understanding of childhood psychiatric disorders, other than to rule out epilepsy or space occupying lesions. However, the advent of computerized, quantitative methods, together with new neuroimaging techniques as brain sources localization and the availability of normative databases both of normal subjects and of subjects with definite pathologies has greatly enhanced the clinical application in neurodevelopmental disorders. Furthermore, in these past years, it has become more and more apparent that groups of patients with neuropsychiatric disorders, who meet symptom based diagnostic criteria for specific disorders (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] or International Classification of Diseases, 10th Revision [ICD-10]) have varied responses to treatment, despite their relatively homogeneous clinical presentation. Using clinical diagnosis, the "treatment of choice" leads to a positive response approximately 60% of the time. (4) This poor response rate suggests heterogeneity within these relatively homogeneous clinical populations. In this direction, the term personalized medicine is becoming more and more common, a medical procedure that separates patients into different groups based on their electrophysiological profiles and predicted response to the quantitative EEG. This has allowed the study of single subjects and to customize health care, with decisions and treatments tailored to each individual patient, as well as improvement of knowledge of the pathophysiological mechanisms of specific diseases.
Currently, the treatment for ADHD is usually pharmacological intervention, such as methylphenidate, Atomoxetine…. etc. However, research has suggested that pharmacological intervention has side effects on nervous system development in children, and the long-term efficacy is uncertain. In recent years, the efficacy of neurofeedback (NF) therapy, as a type of biofeedback method, has been proven in many diseases, such as mild cognitive impairment, epilepsy, and autism, depression and anxiety. Stemming from Skinner's operant conditioned reflexes theory, NF is to enable individuals to actively control and adjust according to their own EEG changes to achieve a certain criterion and finally achieve the purpose of regulating brain function. (5) Neurofeedback (also called neurotherapy or electroencephalogram [EEG] biofeedback) is a type of biofeedback that uses conditioning to train people to improve regulation of their brain-wave patterns by providing them with real-time video/audio information about their brain's electrical activity measured from scalp electrodes. In effect, the conditioning is based on feedback given to the patient that is contingent on the patient's EEG pattern.
First described qualitatively as "brain waves" on the EEG by Hans Berger in 1924, the electrical activity of the brain was thought to reflect changes in the brain's functional state while awake or asleep, or to denote brain diseases such as epilepsy. (6) EEG activity, characterized in terms of rhythmic activity measured in hertz (Hz, the number of waves per second), is divided into specifically named frequency bands, corresponding to functional activity and arousal state: the delta band corresponds to slow-wave sleep state (up to 4 Hz), Theta to a drowsy/inattentive state (4-8 Hz), alpha to a relaxed/wakeful/alert state (8-12 Hz), and beta to an active/attentive state (12-30 Hz).Most of the brain electrical activity occurs in the 1- to 20-Hz range.
Within each band, there are recognizable functionally significant rhythms. For example, a specific type of low beta activity (12-15 Hz) observed in the sensorimotor cortex is called the sensorimotor rhythm. The amplitude of the sensorimotor rhythm is higher when the sensory-motor areas are inactive (eg, during immobile states) and decreases when those areas are activated (eg, during motor tasks). Therefore, the amplitude of the sensorimotor rhythm is a measure of sensory-motor inhibition; that is, higher amplitude when the "brake is on" and lower when the "brake is off." A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG. Event-related potentials are electrical representations associated with sensory and cognitive processing occurring in response to a stimulus or event. (7) Slow cortical potentials (SCPs) are one specific group of event-related potentials. They are slow event-related direct-current shifts of the EEG that correspond to the excitation threshold of large cortical cell assemblies. (8,9) Shifts in the positive direction indicate an increase of the excitation threshold and a corresponding inhibition of activation, whereas shifts in the negative direction, called the contingent negative variation, reflect a reduction of the excitation threshold, and represent cognitive preparation and increased cortical activation of a network. (8,10) The classical conditioning of human EEG was first shown in the mid- 1930s, when researchers trained human subjects to block a wave. (7,8) Operant conditioning, in which EEG-derived information is used as instant feedback to the patient in realtime, was first used to alter the human EEG in the 1960s (11,12,13) Since the 1960s, mainly using operant conditioning, there has been a significant increase in the clinical application of NF to several neuropsychiatric conditions, including ADHD, LD, developmental disabilities, cognitive/memory enhancement, epilepsy, traumatic brain injury, stroke, alcoholism, substance abuse, antisocial personality, autism, anxiety, depression, insomnia, and migraines.(14) There has also been a significant increase, especially in the 21st century, in the number of published research and dissertation studies TYPES OF NEUROFEEDBACK
There are 7 types of NF, Hammond (15) defines their use for various disorders:
- The traditional and most frequently used is Frequency/Power NF, and it is the NF method usually meant by the general term "neurofeedback." This technique typically entails the use of 2 to 4 surface electrodes and is sometimes called "surface neurofeedback." Developed in the 1960s to change the amplitude or speed of specific brain waves in particular brain locations, it is used to treat ADHD, anxiety, insomnia, and LD.
- Slow Cortical Potential Neurofeedback (SCP-NF) modifies the direction (positive or negative) of slow cortical potentials and has been used to treat epilepsy, migraines, and ADHD.
- Low-Energy Neurofeedback System (LENS), developed in 1992, is a passive type of NF involving delivery of a very weak electromagnetic signal to change a patient's brain waves while the patient is motionless and has their eyes closed; it has been used to treat traumatic brain injury, fibromyalgia, anger, restless legs syndrome, ADHD, anxiety, depression, and insomnia.
- Hemoencephalographic (HEG) Neurofeedback, developed in 1994, provides feedback about cerebral blood flow to treat migraine.
- Live Z-score Neurofeedback, developed in 1998, involves the continuous comparison of multiple variables of brain electrical activity (eg, power, asymmetries, phase-lag, coherence) to a normative database to give moment-to-moment feedback; it has been used to treat insomnia.
- Low-Resolution Electromagnetic Tomography (LORETA) was developed in 1994 to treat depression, addictions, and obsessive-compulsive disorder. LORETA involves the use of 19 electrodes that are used to monitor phase, power, and coherence
- The most recent type of NF, developed in 2003, is functional magnetic resonance imaging (fMRI) NF, which allows patients to regulate their brain activity based on feedback of activity from deep subcortical areas of the brain.
NF has been suggested for the treatment of ADHD because research indicates that many patients with ADHD have more slow-wave (especially Theta, 3.5-8 Hz) power and less beta (12-20 Hz) power, especially in the central and frontal regions, as well as reduced cortical negativity (ie, a deviance in contingent negative variation) during cognitive preparation. These brain-wave patterns probably reflect under arousal of the central nervous system associated with the core ADHD symptoms of inattention, hyperactivity, and impulsivity. The goal of this treatment is to reverse these functional characteristics of abnormal CNS physiology by countering the physiological under arousal associated with ADHD.
NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training. (16) This study adopts the theta/beta NF protocol. As a promising nonpharmacological alternative treatment for ADHD, the efficacy of NF has been proven in many studies. Meisel et al. conducted a six-month follow-up trial that compared NF and medication in children with ADHD and discovered significant academic performance improvements in only the NF group (17). One study reported that NF can not only be used as a therapy for many neuropsychiatric disorders but also improve the emotion and cognition of healthy people (18) So the use of quantitative EEG neurofeedback as an add-on therapy can be markedly beneficial to shorten the period of pharmacological treatment and with minimal side effects.
- Conditions
- ADHD
- Being tested
- FDA approved medications for ADHD plus Quantitative EEG Neurofeedback, FDA approved medications for ADHD
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FDA approved medications for ADHD plus Quantitative EEG NeurofeedbackDevice
Also called Drugs + QEEG-NF
A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training.
FDA approved medications for ADHDDrug
Also called Drugs
Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
| Study group | Role | What they receive |
|---|---|---|
| Group A | Placebo comparator | Group A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications Receives: Drug: FDA approved medications for ADHD |
| Group B | Active comparator | Group A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications plus Quantitative EEG Neurofeedback Receives: Device: FDA approved medications for ADHD plus Quantitative EEG Neurofeedback |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement of ADHD manifestations
Greater improvement in ADHD score between group B and Group A
Measured: 6 months
Secondary outcomes (1)
Improvement of intelligence
with the diminished manifestations of ADHD, the IQ is expected to be increased
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2022
- Study start1 Jan 2023 (estimated)
- Primary completion1 Jun 2023 (estimated)
- Study completion1 Jan 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ADHDStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 102 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Emad Eldeen Mahmoud, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05635318
- Sponsor's protocol ID
- QEEG-NF for ADHD
- Status last verified
- Nov 2022
- First submitted
- 23 Nov 2022
- Last updated
- 2 Dec 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Arns M, Drinkenburg W, Leon Kenemans J. The effects of QEEG-informed neurofeedback in ADHD: an open-label pilot study. Appl Psychophysiol Biofeedback. 2012 Sep;37(3):171-80. doi: 10.1007/s10484-012-9191-4.
PubMed 22446998Krepel N, Egtberts T, Sack AT, Heinrich H, Ryan M, Arns M. A multicenter effectiveness trial of QEEG-informed neurofeedback in ADHD: Replication and treatment prediction. Neuroimage Clin. 2020;28:102399. doi: 10.1016/j.nicl.2020.102399. Epub 2020 Aug 25.
PubMed 32891892
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quantitative EEG Neurofeedback as an Add-on Therapy For Attention-deficit Hyperactivity Disorder (ADHD)
- ClinicalTrials.gov ID
- NCT05635318
- Acronym / sponsor ID
- QEEG-NF for ADHD
- Conditions
- ADHD
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 102 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jan 2023 (estimated)
- Primary completion
- 1 Jun 2023 (estimated)
- Study completion
- 1 Jan 2024 (estimated)
- First posted
- 2 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Attention deficit/hyperactivity disorder (ADHD) is a common neurological disorder in children, mainly manifesting as attention deficit, excessive hyperactivity, and impulsivity. It is a chronic condition that affects millions of children and often continues into adulthood.
The prevalence of ADHD in the worldwide is approximately 5%, predominantly occurring in boys, and more than half of patients continue to experience symptoms into adulthood. Children with ADHD have moral disorders and learning difficulties, and these factors will seriously affect their academic achievements and familial and social relationships; thus, treatment is necessary.
Currently, the treatment for ADHD is usually pharmacological intervention, such as methylphenidate, Atomoxetine…. etc. However, research has suggested that pharmacological intervention has side effects on nervous system development in children, and the long-term efficacy is uncertain. In recent years, the efficacy of neurofeedback (NF) therapy, as a type of biofeedback method, has been proven in many diseases, such as mild cognitive impairment, epilepsy, and autism, depression, and anxiety.
NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training. This study adopts the theta/beta NF protocol. As a promising nonpharmacological alternative treatment for ADHD, the efficacy of NF has been proven in many studies.
The use of quantitative EEG neurofeedback as an add-on therapy can be markedly beneficial to shorten the period of pharmacological treatment and with minimal side effects.
Detailed description
Attention deficit/hyperactivity disorder (ADHD) is a common neurological disorder in children, mainly manifesting as attention deficit, excessive hyperactivity, and impulsivity. It is a chronic condition that affects millions of children and often continues into adulthood. ADHD includes a combination of persistent problems, such as difficulty sustaining attention, hyperactivity, and impulsive behavior. Based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), the American Psychiatric Association has divided ADHD into three subtypes: predominantly inattention (ADHD-I), predominantly hyperactive-impulsive (ADHD-HI) and a combination of both (ADHD-C) (1) The prevalence rate of ADHD in the worldwide is approximately 5%, predominantly occurring in boys, and more than half of patients continue to experience symptoms into adulthood (2). Most children with ADHD have moral disorders and learning difficulties, and these factors will seriously affect their academic achievements and familial and social relationships; thus, prompt treatment is necessary. (3) Historically, conventional EEG has added little to the understanding of childhood psychiatric disorders, other than to rule out epilepsy or space occupying lesions. However, the advent of computerized, quantitative methods, together with new neuroimaging techniques as brain sources localization and the availability of normative databases both of normal subjects and of subjects with definite pathologies has greatly enhanced the clinical application in neurodevelopmental disorders. Furthermore, in these past years, it has become more and more apparent that groups of patients with neuropsychiatric disorders, who meet symptom based diagnostic criteria for specific disorders (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] or International Classification of Diseases, 10th Revision [ICD-10]) have varied responses to treatment, despite their relatively homogeneous clinical presentation. Using clinical diagnosis, the "treatment of choice" leads to a positive response approximately 60% of the time. (4) This poor response rate suggests heterogeneity within these relatively homogeneous clinical populations. In this direction, the term personalized medicine is becoming more and more common, a medical procedure that separates patients into different groups based on their electrophysiological profiles and predicted response to the quantitative EEG. This has allowed the study of single subjects and to customize health care, with decisions and treatments tailored to each individual patient, as well as improvement of knowledge of the pathophysiological mechanisms of specific diseases.
Currently, the treatment for ADHD is usually pharmacological intervention, such as methylphenidate, Atomoxetine…. etc. However, research has suggested that pharmacological intervention has side effects on nervous system development in children, and the long-term efficacy is uncertain. In recent years, the efficacy of neurofeedback (NF) therapy, as a type of biofeedback method, has been proven in many diseases, such as mild cognitive impairment, epilepsy, and autism, depression and anxiety. Stemming from Skinner's operant conditioned reflexes theory, NF is to enable individuals to actively control and adjust according to their own EEG changes to achieve a certain criterion and finally achieve the purpose of regulating brain function. (5) Neurofeedback (also called neurotherapy or electroencephalogram [EEG] biofeedback) is a type of biofeedback that uses conditioning to train people to improve regulation of their brain-wave patterns by providing them with real-time video/audio information about their brain's electrical activity measured from scalp electrodes. In effect, the conditioning is based on feedback given to the patient that is contingent on the patient's EEG pattern.
First described qualitatively as "brain waves" on the EEG by Hans Berger in 1924, the electrical activity of the brain was thought to reflect changes in the brain's functional state while awake or asleep, or to denote brain diseases such as epilepsy. (6) EEG activity, characterized in terms of rhythmic activity measured in hertz (Hz, the number of waves per second), is divided into specifically named frequency bands, corresponding to functional activity and arousal state: the delta band corresponds to slow-wave sleep state (up to 4 Hz), Theta to a drowsy/inattentive state (4-8 Hz), alpha to a relaxed/wakeful/alert state (8-12 Hz), and beta to an active/attentive state (12-30 Hz).Most of the brain electrical activity occurs in the 1- to 20-Hz range.
Within each band, there are recognizable functionally significant rhythms. For example, a specific type of low beta activity (12-15 Hz) observed in the sensorimotor cortex is called the sensorimotor rhythm. The amplitude of the sensorimotor rhythm is higher when the sensory-motor areas are inactive (eg, during immobile states) and decreases when those areas are activated (eg, during motor tasks). Therefore, the amplitude of the sensorimotor rhythm is a measure of sensory-motor inhibition; that is, higher amplitude when the "brake is on" and lower when the "brake is off." A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG. Event-related potentials are electrical representations associated with sensory and cognitive processing occurring in response to a stimulus or event. (7) Slow cortical potentials (SCPs) are one specific group of event-related potentials. They are slow event-related direct-current shifts of the EEG that correspond to the excitation threshold of large cortical cell assemblies. (8,9) Shifts in the positive direction indicate an increase of the excitation threshold and a corresponding inhibition of activation, whereas shifts in the negative direction, called the contingent negative variation, reflect a reduction of the excitation threshold, and represent cognitive preparation and increased cortical activation of a network. (8,10) The classical conditioning of human EEG was first shown in the mid- 1930s, when researchers trained human subjects to block a wave. (7,8) Operant conditioning, in which EEG-derived information is used as instant feedback to the patient in realtime, was first used to alter the human EEG in the 1960s (11,12,13) Since the 1960s, mainly using operant conditioning, there has been a significant increase in the clinical application of NF to several neuropsychiatric conditions, including ADHD, LD, developmental disabilities, cognitive/memory enhancement, epilepsy, traumatic brain injury, stroke, alcoholism, substance abuse, antisocial personality, autism, anxiety, depression, insomnia, and migraines.(14) There has also been a significant increase, especially in the 21st century, in the number of published research and dissertation studies TYPES OF NEUROFEEDBACK
There are 7 types of NF, Hammond (15) defines their use for various disorders:
- The traditional and most frequently used is Frequency/Power NF, and it is the NF method usually meant by the general term "neurofeedback." This technique typically entails the use of 2 to 4 surface electrodes and is sometimes called "surface neurofeedback." Developed in the 1960s to change the amplitude or speed of specific brain waves in particular brain locations, it is used to treat ADHD, anxiety, insomnia, and LD.
- Slow Cortical Potential Neurofeedback (SCP-NF) modifies the direction (positive or negative) of slow cortical potentials and has been used to treat epilepsy, migraines, and ADHD.
- Low-Energy Neurofeedback System (LENS), developed in 1992, is a passive type of NF involving delivery of a very weak electromagnetic signal to change a patient's brain waves while the patient is motionless and has their eyes closed; it has been used to treat traumatic brain injury, fibromyalgia, anger, restless legs syndrome, ADHD, anxiety, depression, and insomnia.
- Hemoencephalographic (HEG) Neurofeedback, developed in 1994, provides feedback about cerebral blood flow to treat migraine.
- Live Z-score Neurofeedback, developed in 1998, involves the continuous comparison of multiple variables of brain electrical activity (eg, power, asymmetries, phase-lag, coherence) to a normative database to give moment-to-moment feedback; it has been used to treat insomnia.
- Low-Resolution Electromagnetic Tomography (LORETA) was developed in 1994 to treat depression, addictions, and obsessive-compulsive disorder. LORETA involves the use of 19 electrodes that are used to monitor phase, power, and coherence
- The most recent type of NF, developed in 2003, is functional magnetic resonance imaging (fMRI) NF, which allows patients to regulate their brain activity based on feedback of activity from deep subcortical areas of the brain.
NF has been suggested for the treatment of ADHD because research indicates that many patients with ADHD have more slow-wave (especially Theta, 3.5-8 Hz) power and less beta (12-20 Hz) power, especially in the central and frontal regions, as well as reduced cortical negativity (ie, a deviance in contingent negative variation) during cognitive preparation. These brain-wave patterns probably reflect under arousal of the central nervous system associated with the core ADHD symptoms of inattention, hyperactivity, and impulsivity. The goal of this treatment is to reverse these functional characteristics of abnormal CNS physiology by countering the physiological under arousal associated with ADHD.
NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training. (16) This study adopts the theta/beta NF protocol. As a promising nonpharmacological alternative treatment for ADHD, the efficacy of NF has been proven in many studies. Meisel et al. conducted a six-month follow-up trial that compared NF and medication in children with ADHD and discovered significant academic performance improvements in only the NF group (17). One study reported that NF can not only be used as a therapy for many neuropsychiatric disorders but also improve the emotion and cognition of healthy people (18) So the use of quantitative EEG neurofeedback as an add-on therapy can be markedly beneficial to shorten the period of pharmacological treatment and with minimal side effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | Placebo comparator | Drug: FDA approved medications for ADHDGroup A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications |
| Group B | Active comparator | Device: FDA approved medications for ADHD plus Quantitative EEG NeurofeedbackGroup A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications plus Quantitative EEG Neurofeedback |
Who may qualify
- Ages
- 4 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Patients diagnosed with ADHD according to DSM-5 Criteria for ADHD Age group: 4 years up to less than 16 years
Key exclusion criteria (2 listed)
- *Any patient with other neurological or psychological diseases e.g. Epilepsy, Autism, Cerebral palsy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FDA approved medications for ADHD plus Quantitative EEG NeurofeedbackAlso: Drugs + QEEG-NFA mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training. | Device | Group B |
| FDA approved medications for ADHDAlso: DrugsRitalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl) | Drug | Group A |
Primary outcome
Improvement of ADHD manifestations
Time frame: 6 months
Greater improvement in ADHD score between group B and Group A
1 secondary outcome
Improvement of intelligence
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2022.
- Background: PubMed 22446998Arns M, Drinkenburg W, Leon Kenemans J. The effects of QEEG-informed neurofeedback in ADHD: an open-label pilot study. Appl Psychophysiol Biofeedback. 2012 Sep;37(3):171-80. doi: 10.1007/s10484-012-9191-4.
- Background: PubMed 32891892Krepel N, Egtberts T, Sack AT, Heinrich H, Ryan M, Arns M. A multicenter effectiveness trial of QEEG-informed neurofeedback in ADHD: Replication and treatment prediction. Neuroimage Clin. 2020;28:102399. doi: 10.1016/j.nicl.2020.102399. Epub 2020 Aug 25.
Related trials for ADHD
Not yet recruiting
Cognitive-Motor Training With the DextEgg in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingObservational study
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy
Irritability, Disruptive Mood Dysregulation Disorder
Active, not recruiting
Digital Therapeutics for Behavior Problems
Problem Behavior, Child Behavior
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Acupuncture for ADHD: Acupoint Data Mining, Clinical Effectiveness, and Interviews to Explore Treatment Outcomes.
Acupuncture, ADHD - Attention Deficit Disorder With Hyperactivity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A study testing FDA approved medications for ADHD plus Quantitative EEG Neurofeedback and FDA approved medications for ADHD in people with ADHD, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact El-Sayed Khalil Abdel-Karim, Professor (01556588807, Khalilsay53@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement of ADHD manifestations (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05635318, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2022.